Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma.
Xudong ZhuXingming ZhangGuangxi SunZhenhua LiuHaoran ZhangYaojing YangYuchao NiJindong DaiSha ZhuJunru ChenJinge ZhaoZhipeng WangHao ZengPeng-Fei ShenPublished in: Cancer management and research (2021)
Treatment-related toxicities could be minimized through plasma concentration monitoring. Patients with adjusted schedules by therapeutic drug monitoring could achieve better survival benefits.